The section of the announcement saying,
"Subject to the successful results of the Phase IIb Trial, we then plan to be able to commence commercial scale treatment of ovarian cancer patients in Australia and New Zealand."
has also been in previous announcements. I believe I posted this answer from MR when I made enquiries with him at the time,
'We expect to receive market revenue in Australia and New Zealand as the ANZGOG have given us an undertaking that they will prescribe to their patients'.
Thats correct 'market revenue'. Also, consider whether people will travel to Australia to receive this treatment, and the figures that Dendreon have mentioned re their intended pricing for Provenge.
I also e-mailed ANZGOG re prima and Cvac, however I never received a reply, which is what I expected.
Regards
dc
great update, page-5
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
0.020(6.90%) |
Mkt cap ! $450.9M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 31.5¢ | 29.0¢ | $1.805M | 5.903M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 193400 | 30.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 11/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |